- Home
- FRSH vs ALKS Comparison
FRSH vs ALKS Comparison
Compare FRSH & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRSH
- ALKS
- Stock Information
- Founded
- FRSH 2010
- ALKS 1987
- Country
- FRSH United States
- ALKS Ireland
- Employees
- FRSH N/A
- ALKS N/A
- Industry
- FRSH EDP Services
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- FRSH Technology
- ALKS Health Care
- Exchange
- FRSH Nasdaq
- ALKS Nasdaq
- Market Cap
- FRSH N/A
- ALKS 5.4B
- IPO Year
- FRSH 2021
- ALKS 1991
- Fundamental
- Price
- FRSH $14.33
- ALKS $32.53
- Analyst Decision
- FRSH Buy
- ALKS Buy
- Analyst Count
- FRSH 13
- ALKS 13
- Target Price
- FRSH $20.62
- ALKS $39.50
- AVG Volume (30 Days)
- FRSH 2.7M
- ALKS 1.7M
- Earning Date
- FRSH 04-30-2025
- ALKS 04-30-2025
- Dividend Yield
- FRSH N/A
- ALKS N/A
- EPS Growth
- FRSH N/A
- ALKS 3.47
- EPS
- FRSH N/A
- ALKS 2.17
- Revenue
- FRSH $720,420,000.00
- ALKS $1,557,632,000.00
- Revenue This Year
- FRSH $15.45
- ALKS N/A
- Revenue Next Year
- FRSH $13.26
- ALKS $4.37
- P/E Ratio
- FRSH N/A
- ALKS $15.02
- Revenue Growth
- FRSH 20.79
- ALKS N/A
- 52 Week Low
- FRSH $10.81
- ALKS $22.90
- 52 Week High
- FRSH $19.77
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- FRSH 36.52
- ALKS 38.54
- Support Level
- FRSH $13.77
- ALKS $32.05
- Resistance Level
- FRSH $16.48
- ALKS $34.45
- Average True Range (ATR)
- FRSH 0.54
- ALKS 0.96
- MACD
- FRSH -0.05
- ALKS -0.26
- Stochastic Oscillator
- FRSH 20.66
- ALKS 14.29
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.